A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 137-142

  Han, Ji Youn ^a   Kim, Hyae Young ^a   Lim, Kun Young ^a   Han, Jong Hee ^a   Lee, You Jin ^a   Kwak, Mi Hyang ^a   Kim, Hak Jin ^a   Yun, Tak ^a   Kim, Heung Tae ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Angiogenesis; KIT; Recurrence; SCLC; Sunitinib; VEGF

Indexed keywords

SUNITINIB;

ADULT; AGED; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CYTOPATHOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; LUNG SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ASTHENIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PYRROLES; SMALL CELL LUNG CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84872157738     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.019     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Simon G.R., Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:324S-339S.
3. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
4. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090-2096.
5. Lucchi M., Mussi A., Fontanini G., Faviana P., Ribechini A., Angeletti C.A. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002, 21:1105-1110.
6. Tanno S., Ohsaki Y., Nakanishi K., Toyoshima E., Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004, 46:11-19.
7. Ioannou M., Papamichali R., Kouvaras E., Mylonis I., Vageli D., Kerenidou T., et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 2009, 187:321-329.
8. Ustuner Z., Saip P., Yasasever V., Vural B., Yazar A., Bal C., et al. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol 2008, 25:394-399.
9. Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006, 24:492-496.
10. Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998, 79:144-146.
11. Zhan P., Wang J., Lv X.J., Wang Q., Qiu L.X., Lin X.Q., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009, 4:1094-1103.
12. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56:370-376.
13. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
14. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
15. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
18. Tarhini A., Kotsakis A., Gooding W., Shuai Y., Petro D., Friedland D., et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010, 16:5900-5907.
19. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
20. Houk B.E., Bello C.L., Kang D., Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009, 15:2497-2506.
21. Torino F., Corsello S.M., Longo R., Barnabei A., Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228.
22. Spigel D.R., Townley P.M., Waterhouse D.M., Fang L., Adiguzel I., Huang J.E., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011, 29:2215-2222.
23. Lee S.M., Woll P.J., Rudd R., Ferry D., O'Brien M., Middleton G., et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009, 101:1049-1057.
24. Ramalingam S.S., Belani C.P., Mack P.C., Vokes E.E., Longmate J., Govindan R., et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010, 5:1279-1284.
25. Arnold A.M., Seymour L., Smylie M., Ding K., Ung Y., Findlay B., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20. J Clin Oncol 2007, 25:4278-4284.
26. Schneider B.J., Gadgeel S.M., Ramnath N., Wozniak A.J., Dy G.K., Daignault S., et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011, 6:1117-1120.